Life Science Leader Features Stefan Weber, CEO of Newron Pharmaceuticals SpA, on Drug Company Discovery & Commercialization

newron-logo

lsl

Drug Company Discovery & Commercialization: An Election Year Analogy

stefanweberBy Stefan Weber, CEO and Executive Director, Newron Pharmaceuticals SpA

When smaller, boutique drug companies move from precommercial discovery to postcommercial marketing, they can experience a shock. Precommercial work is typically rigorous and controlled with trials conducted in sequential fashion and oversight done by recognized governing bodies. Of course there can be detours along the way, but generally speaking, the path itself is well-known. In contrast, postcommercial work expands the ecosystem and, therefore, brings with it an increasing number of participants, functions, relationships, and unknowns.

To continue reading this story, subscribe to Life Science Leader.